サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1777386

肝疾患診断の世界市場

Liver Disease Diagnostics

出版日
ページ情報
英文 380 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
肝疾患診断の世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 380 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肝疾患診断の世界市場は2030年までに496億米ドルに達する見込み

2024年に366億米ドルと推定される肝疾患診断の世界市場は、分析期間2024-2030年にCAGR 5.2％で成長し、2030年には496億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである臨床検査は、CAGR 5.4%を記録し、分析期間終了時には168億米ドルに達すると予測されます。画像診断分野の成長率は、分析期間中CAGR 3.9%と推定されます。

米国市場は100億米ドルと推定、中国はCAGR 8.3％で成長予測

米国の肝疾患診断市場は、2024年に100億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに99億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5%と5.2%と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

世界の肝疾患診断市場- 主要動向と促進要因のまとめ

肝疾患診断が重要性を増している理由

肝炎、脂肪性肝疾患、肝硬変、肝細胞がん（HCC）などの肝疾患の有病率の増加が、高度な診断ソリューションの需要を促進しています。肝疾患は、アルコール摂取、肥満、代謝異常などのライフスタイル要因によって悪化し、依然として世界的に大きな健康負担となっています。非アルコール性脂肪性肝疾患（NAFLD）や非アルコール性脂肪性肝炎（NASH）の罹患率の上昇により、早期かつ正確な診断の必要性がさらに高まっています。肝機能検査、画像技術、生検といった従来の診断方法は、先進的なバイオマーカーに基づくアッセイ、非侵襲的画像ソリューション、AI主導の診断プラットフォームによって補完されつつあります。各国政府やヘルスケア機関は、罹患率や死亡率の低下におけるタイムリーな介入の重要性を認識し、疾患の早期発見に対する認識や資金提供を高めています。さらに、個別化医療へのシフトは、革新的な肝疾患診断ツールの必要性をさらに煽り、個々の危険因子や疾患の進行に基づいたオーダーメイドの治療アプローチを可能にしています。

どのような技術革新が肝疾患診断を強化しているのか？

技術の進歩は、肝疾患診断の精度、効率性、アクセシビリティを大幅に向上させています。最も注目すべき技術革新の一つは、エラストグラフィーのような非侵襲的診断技術の開発で、生検の必要なく肝臓の硬さを評価し線維化を検出します。AIを搭載した画像ソリューションも、自動化されたパターン認識と予測分析によって肝臓異常の検出を強化することで、診断に革命をもたらしています。リキッドバイオプシー技術の登場も画期的で、血液サンプルから肝疾患のバイオマーカーを検出できるようになり、侵襲的な処置の必要性が減少しました。さらに、ゲノミクス、プロテオミクス、メタボロミクスを統合したマルチオミクス・アプローチは、肝疾患の病態生理と進行に関する深い洞察をもたらしています。遠隔医療と遠隔診断ソリューションの統合は、特に十分なサービスを受けていない地域における肝疾患スクリーニングへのアクセスをさらに拡大しつつあります。研究開発が進むにつれて、次世代診断ツールは世界中の肝疾患患者の早期発見率と治療成績の向上に重要な役割を果たすことになるでしょう。

消費者動向とヘルスケア政策は市場をどのように形成しているか？

消費者の嗜好の変化とヘルスケア政策の進化が、肝疾患診断市場の成長に重要な役割を果たしています。肝臓の健康と予防検診に対する意識の高まりは、特に高リスク集団において、定期的な診断検査を求める個人を増やしています。家庭用検査キットやデジタルヘルスソリューションの採用により、肝疾患診断は消費者にとってより便利で利用しやすいものとなっています。さらに、早期発見を促進する政府の取り組みや公衆衛生キャンペーンが、検診プログラムへの需要を高めています。ヘルスケアプロバイダーや保険会社も、肝疾患の早期発見の費用対効果を認識しており、高度な診断検査の保険適用拡大につながっています。さらに、製薬会社と診断薬開発企業とのコラボレーションにより、新しい肝疾患診断技術の商業化が加速しています。慢性肝疾患の負担を軽減することが世界的に重視されているため、規制当局は革新的な診断ソリューションの承認を迅速に進め、市場への浸透と普及を確実なものにしています。

肝疾患診断市場を促進する主な成長要因は？

肝疾患診断市場の成長は、肝疾患の有病率の増加、技術の進歩、ヘルスケア政策の支援など、いくつかの要因によって牽引されています。B型肝炎やC型肝炎、NAFLD、NASHの罹患率の増加は、早期かつ正確な診断ツールに対する強い需要を生み出しています。画像診断技術、バイオマーカー探索、AI主導の診断プラットフォームにおける革新は、肝疾患検出の精度とアクセシビリティを向上させています。また、ポイントオブケア検査や携帯型診断機器の役割の拡大により、早期診断と患者モニタリングが強化されています。さらに、遠隔医療やAIによる意思決定支援などのデジタルヘルス技術の統合により、診断ワークフローが合理化され、患者の転帰が改善されつつあります。予防ヘルスケアと定期的な肝機能スクリーニングへの注目の高まりは、市場の拡大をさらに後押ししています。さらに、研究開発への投資の増加と新規診断技術に対する規制当局の支援により、革新的ソリューションの安定したパイプラインが確保されています。世界のヘルスケアシステムが疾患の早期発見と個別化医療を優先する中、肝疾患診断市場は持続的な成長を遂げ、患者ケアと治療戦略の改善に道を開くと期待されています。

セグメント

診断技術（臨床検査、画像診断、内視鏡検査、生検、その他）;疾患（NAFLD、NASH、線維症、肝硬変、HCC、その他）;エンドユーザー（病院、研究所、その他）

調査対象企業の例

  • Abbott
  • BioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Biosino Bio-Technology and Science Inc
  • Boston Scientific Corporation
  • DiaSorin
  • Echosens
  • Enterome
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Corporation
  • Genentech（a member of the Roche Group）
  • Horiba Medical
  • Laboratory Corporation of America Holdings（LabCorp）
  • Owlstone Medical
  • Perspectum
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

AI統合

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP31871

Global Liver Disease Diagnostics Market to Reach US$49.6 Billion by 2030

The global market for Liver Disease Diagnostics estimated at US$36.6 Billion in the year 2024, is expected to reach US$49.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$16.8 Billion by the end of the analysis period. Growth in the Imaging segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.0 Billion While China is Forecast to Grow at 8.3% CAGR

The Liver Disease Diagnostics market in the U.S. is estimated at US$10.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.9 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Liver Disease Diagnostics Market - Key Trends & Drivers Summarized

Why Is Liver Disease Diagnostics Gaining Critical Importance?

The increasing prevalence of liver diseases, including hepatitis, fatty liver disease, cirrhosis, and hepatocellular carcinoma (HCC), is driving the demand for advanced diagnostic solutions. Liver disease remains a significant global health burden, exacerbated by lifestyle factors such as alcohol consumption, obesity, and metabolic disorders. The rising incidence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has further intensified the need for early and accurate diagnostics. Traditional diagnostic methods such as liver function tests, imaging techniques, and biopsies are being supplemented by advanced biomarker-based assays, non-invasive imaging solutions, and AI-driven diagnostic platforms. Governments and healthcare organizations are increasing awareness and funding for early disease detection, recognizing the importance of timely intervention in reducing morbidity and mortality rates. Additionally, the shift towards personalized medicine is further fueling the need for innovative liver disease diagnostic tools, enabling tailored treatment approaches based on individual risk factors and disease progression.

What Innovations Are Enhancing Liver Disease Diagnostics?

Technological advancements are significantly improving the accuracy, efficiency, and accessibility of liver disease diagnostics. One of the most notable innovations is the development of non-invasive diagnostic techniques, such as elastography, which assesses liver stiffness and detects fibrosis without the need for a biopsy. AI-powered imaging solutions are also revolutionizing diagnostics by enhancing the detection of liver abnormalities through automated pattern recognition and predictive analytics. The emergence of liquid biopsy technology is another breakthrough, allowing for the detection of liver disease biomarkers in blood samples, reducing the need for invasive procedures. Additionally, multi-omics approaches, integrating genomics, proteomics, and metabolomics, are offering deeper insights into liver disease pathophysiology and progression. The integration of telemedicine and remote diagnostic solutions is further expanding access to liver disease screening, particularly in underserved regions. As research and development continue to advance, next-generation diagnostic tools will play a critical role in improving early detection rates and treatment outcomes for liver disease patients worldwide.

How Are Consumer Trends and Healthcare Policies Shaping the Market?

Shifting consumer preferences and evolving healthcare policies are playing a crucial role in the growth of the liver disease diagnostics market. The rising awareness of liver health and preventive screening is driving more individuals to seek regular diagnostic testing, particularly in high-risk populations. The adoption of at-home testing kits and digital health solutions is making liver disease diagnostics more convenient and accessible to consumers. Additionally, government initiatives and public health campaigns promoting early detection are fostering higher demand for screening programs. Healthcare providers and insurance companies are also recognizing the cost-effectiveness of early liver disease detection, leading to expanded coverage for advanced diagnostic tests. Furthermore, collaborations between pharmaceutical companies and diagnostic developers are accelerating the commercialization of novel liver disease diagnostic technologies. The global emphasis on reducing the burden of chronic liver conditions is driving regulatory agencies to fast-track approvals for innovative diagnostic solutions, ensuring wider market penetration and adoption.

What Are the Key Growth Drivers Fueling the Liver Disease Diagnostics Market?

The growth in the liver disease diagnostics market is driven by several factors, including the increasing prevalence of liver disorders, technological advancements, and supportive healthcare policies. The rising incidence of hepatitis B and C, NAFLD, and NASH is creating a strong demand for early and accurate diagnostic tools. Innovations in imaging techniques, biomarker discovery, and AI-driven diagnostic platforms are improving the precision and accessibility of liver disease detection. The expanding role of point-of-care testing and portable diagnostic devices is also enhancing early diagnosis and patient monitoring. Additionally, the integration of digital health technologies, such as telemedicine and AI-assisted decision support, is streamlining diagnostic workflows and improving patient outcomes. The growing focus on preventive healthcare and routine liver function screening is further bolstering market expansion. Moreover, increasing investments in research and development, coupled with regulatory support for novel diagnostic technologies, are ensuring a steady pipeline of innovative solutions. As global healthcare systems prioritize early disease detection and personalized medicine, the liver disease diagnostics market is expected to witness sustained growth, paving the way for improved patient care and treatment strategies.

SCOPE OF STUDY:

The report analyzes the Liver Disease Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnosis Technique (Laboratory Tests, Imaging, Endoscopy, Biopsy, Others); Disease (NAFLD, NASH, Fibrosis, Cirrhosis, HCC, Others); End-Use (Hospitals, Laboratories, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Abbott
  • BioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Biosino Bio-Technology and Science Inc
  • Boston Scientific Corporation
  • DiaSorin
  • Echosens
  • Enterome
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Corporation
  • Genentech (a member of the Roche Group)
  • Horiba Medical
  • Laboratory Corporation of America Holdings (LabCorp)
  • Owlstone Medical
  • Perspectum
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Liver Disease Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of NAFLD and NASH Throws the Spotlight on Advanced Liver Disease Diagnostics
    • OEM Innovation in Non-Invasive Biomarker Assays Drives Demand for Early Detection and Monitoring Tools
    • Expansion of Fibrosis and Cirrhosis Screening Programs Propels Use of Imaging and Blood-Based Diagnostic Platforms
    • Growth in Liver Transplant and Hepatology Clinics Spurs Adoption of High-Sensitivity Diagnostics
    • OEM Focus on AI-Driven Elastography and MRI Analysis Enhances Imaging Accuracy and Predictive Value
    • Regulatory Endorsements for Non-Invasive Diagnostics Accelerate Shift Away From Liver Biopsies
    • Surge in Point-of-Care Diagnostic Devices Enables Decentralized Liver Health Screening in Primary Care
    • OEM Development of Combined Liver Function Panels and Risk Scoring Tools Supports Integrated Clinical Decisions
    • Rising Prevalence of Metabolic Syndrome and Obesity Expands Addressable Population for Liver Diagnostics
    • OEM Partnerships With Pharma Companies Enable Companion Diagnostics in NASH and Hepatitis C Therapeutics
    • Growing Demand for Early-Stage Detection in Oncology Fuels Innovation in HCC-Specific Biomarker Panels
    • Expansion of Mobile Diagnostic Units and Community Health Initiatives Promotes Broader Access to Liver Testing
    • OEM Emphasis on Patient-Friendly Sample Collection Methods Enhances Compliance in Chronic Disease Monitoring
    • Regulatory Alignment on Diagnostic Performance Thresholds Supports Global Deployment of Standardized Tests
    • Increased Use of Liver Health Assessment in Pre-Operative Screening and Risk Stratification Drives Routine Testing
    • OEM Collaboration With Digital Health Providers Enables Remote Liver Health Monitoring and Data Integration
    • Growth in Awareness Campaigns and Preventive Health Check Programs Strengthens Uptake in Undiagnosed Populations
    • Rising Incidence of Alcohol-Related Liver Disease Supports Demand for Longitudinal Disease Monitoring Tools
    • OEM Strategies for Combining Genomic, Proteomic, and Metabolomic Data Enhance Diagnostic Precision
    • Focus on Diagnostic Value in Drug-Induced Liver Injury (DILI) Detection Expands Use in Pharmacovigilance Programs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Liver Disease Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Liver Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Liver Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Laboratory Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Laboratory Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Laboratory Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Endoscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Endoscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Endoscopy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Diagnosis Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Diagnosis Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Diagnosis Techniques by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for HCC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for NAFLD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for NAFLD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for NAFLD by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for NASH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for NASH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for NASH by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Cirrhosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Cirrhosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Cirrhosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Liver Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Liver Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 95: France Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Italy 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 122: UK Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: UK 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Spain 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Russia 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Liver Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Australia 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Australia 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 179: India Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: India 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 185: India Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: India 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: South Korea 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: South Korea 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Liver Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Liver Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Latin America 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Latin America 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Argentina 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Argentina 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Brazil 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Brazil 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Mexico 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Mexico 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Liver Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Liver Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Middle East 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Middle East 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Iran 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Iran 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Israel 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Israel 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: UAE 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: UAE 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Africa 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Africa 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION